Page last updated: 2024-10-26

etidronate and Nausea

etidronate has been researched along with Nausea in 4 studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

Research Excerpts

ExcerptRelevanceReference
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."9.14Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)
"The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)."5.14Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Markopoulos, C1
Tzoracoleftherakis, E1
Polychronis, A1
Venizelos, B1
Dafni, U1
Xepapadakis, G1
Papadiamantis, J1
Zobolas, V1
Misitzis, J1
Kalogerakos, K1
Sarantopoulou, A1
Siasos, N1
Koukouras, D1
Antonopoulou, Z1
Lazarou, S1
Gogas, H1
Barrera, BA1
Wilton, L1
Harris, S1
Shakir, SA1
Evans, RA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484]220 participants (Actual)Observational2004-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for etidronate and Nausea

ArticleYear
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Breast cancer research : BCR, 2010, Volume: 12, Issue:2

    Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit

2010

Other Studies

3 other studies available for etidronate and Nausea

ArticleYear
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents;

2005
Treatment of Paget's disease of bone.
    The Medical journal of Australia, 1983, Feb-19, Volume: 1, Issue:4

    Topics: Aged; Alkaline Phosphatase; Calcitonin; Calcium; Chlorthalidone; Dose-Response Relationship, Drug; E

1983
Risedronate for Paget's disease of bone.
    The Medical letter on drugs and therapeutics, 1998, Aug-28, Volume: 40, Issue:1034

    Topics: Administration, Oral; Aged; Bone Resorption; Calcium Channel Blockers; Clinical Trials as Topic; Dia

1998